NCT07218666View on ClinicalTrials.gov

Zanzalintinib in Men With Aggressive Variant Prostate Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

May 31, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Aggressive Variant Prostate Carcinoma

Interventions

DRUG

Zanzalintinib

Zanzalintinib 60mg orally (PO) once daily in

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Exelixis

INDUSTRY

collaborator

Medical College of Wisconsin

OTHER

lead

Deepak Kilari

OTHER